ADC Therapeutics SA Sustainability Reports
ADC Therapeutics SA is a commercial-stage biotechnology company focused on developing next-generation targeted antibody-drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. Its pipeline includes its FDA-approved lead product, ZYNLONTA, for the treatment of relapsed or refractory large B-cell lymphoma.
Sector: Manufacturing
Country: Switzerland
Exchange: New York Stock Exchange
FIGI: BBG00Q6Q3RN0
7 reports from 2020 to 2025
